BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: A non-specific beneficial effect of BCG?
Introduction
The bacille Calmette–Guérin (BCG) vaccine was first given to humans in 1921 [1], and came into common use in many countries during the 1930s [2], [3]. The vaccine protects against tuberculosis (TB) [4] and leprosy [5], but the efficacy against TB varies a lot between countries [6]. Recent research has provided support for the hypothesis that the variation in BCG vaccine efficacy can be ascribed to prior sensitisation with environmental mycobacteriae [7].
BCG vaccination is known to stimulate cell-mediated immunity, and BCG immunotherapy has for many decades been used in the treatment of bladder cancer resulting in improved survival [8]. Several studies investigated the effect of BCG vaccination on other cancer forms, but results in terms of survival have been contradictory [9]. In West Africa we found BCG vaccination of infants to be associated with a Th1-biased immune response [10], increased antibody response to unrelated antigen [11], less atopy [12], less anergy [13] and a reduction in childhood mortality [14]. Cutaneous anergy to tuberculin and panels of antigens has been associated with decreased survival in adults [15], [16].
If the difference in mortality between BCG-vaccinated and BCG-unvaccinated children [14] is due to the vaccine and not a result of selection bias between vaccinated and unvaccinated children, we hypothesise that the strongest beneficial effect should be found among children with a BCG scar or a positive tuberculin reaction. In connection with a vaccine trial in Guinea-Bissau, we obtained data on BCG scar status and tuberculin reaction in BCG-vaccinated infants and their subsequent childhood mortality. Since TB is also studied in this community, we examined whether the effect of BCG was related to better protection against household exposure to TB.
Section snippets
Routine vaccination programme in Guinea-Bissau
BCG and the first oral polio vaccine (OPV) are given at birth. OPV and the diphtheria–tetanus–pertussis (DTP) vaccine are given at 6, 10 and 14 weeks, and sometimes a booster dose at 18 months of age. The measles vaccine is routinely given at 9 months of age. The Bandim Health Project gave the measles vaccinations, the other vaccines were administered by the Expanded Programme on Immunisations (EPI) in Bissau.
BCG vaccination
Vaccination status was obtained via the routine surveillance system and double-checked
Study individuals
Fifty-nine percent (479/813) had a positive reaction to old tuberculin, 33% (268/813) to diphtheria, and 47% (384/813) to tetanus. The median diameter (mm) of positive reactions (range) was 4.0 (2.0–11.0) for tuberculin, 3.5 (2.0–6.5) for diphtheria, and 4.0 (2.0–12.5) for tetanus [13]. Among measles vaccinated children there was no difference in tuberculin positivity whether the child had received measles vaccine less than, 56% (73/130), or more than 6 weeks before skin-testing, 60% (168/282),
Discussion
We found BCG scar and a positive tuberculin reaction to be associated with better survival in BCG-vaccinated children. BCG vaccination has recently been associated with reduction in mortality [14]. To our knowledge, this is the first report to link BCG scar and a positive tuberculin response after BCG vaccination with better survival in childhood. Our study provides evidence that this effect is unlikely to be due to improved protection against TB as exclusion of children exposed to TB had no
Contributors
The study was planned by PA, MLG, IML, and HW. CLM, CB, MAB and MLG managed the two-dose trial and carried out the child examinations for the present study. PG managed the community study of TB. IML carried out the T-cell analyses. KLH carried out the statistical analyses. PA suggested the first analyses, MLG wrote the first draft of the paper and all authors contributed to the final version of the paper.
Acknowledgements
We are grateful to the following for logistic or financial support: Ministry of Public Health, Guinea-Bissau; Danish Council for Development Research; Danish Medical Research Council (SSVF 9700716); and the Science and Technology for Development Programme of the European Community (TS3∗CT91∗0002 and ERBIC 18 CT95∗0011). We thank Professor Per Kragh Andersen for his assistance with the statistical analyses, and Ms. Ramu Sarge-Njee and Mrs. Elishia Roberts for the HIV-testing.
References (52)
Variation in protection by BCG: implications of and for heterologous immunity
Lancet
(1995)- et al.
BCG immunotherapy of bladder cancer: 20 years on
Lancet
(1999) - et al.
BCG vaccination and cancer
Tubercle
(1990) - et al.
BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria–tetanus antigens
Vaccine
(2001) - et al.
Skin anergy and tuberculosis
Respir. Med.
(1992) - et al.
Labelling of T cell subsets under field conditions in tropical countries. Adaptation of the immuno-alkaline phosphatase staining method for blood smears
J. Immunol. Methods
(1990) - et al.
Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India
Tuberc. Lung Dis.
(1999) - et al.
Child survival in children born to HIV-2 infected women in Guinea-Bissau, West Africa
Acta Trop.
(1999) - et al.
Delayed-type hypersensitivity skin testing in human immunodeficiency virus-infected pediatric patients
J. Pediatr.
(1996) Bacille Calmette–Guérin vaccines: a rough guide
Clin. Infect. Dis.
(1995)